Rhumbline Advisers Adagio Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 84,017 shares of ADGI stock, worth $278,096. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,017
Previous 1,853
4434.11%
Holding current value
$278,096
Previous $6,000
4533.33%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ADGI
# of Institutions
82Shares Held
67.3MCall Options Held
720KPut Options Held
600-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.77% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.19% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million35.29% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.3MShares$14.2 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...